Vorinostat(SAHA)
Names
[ CAS No. ]:
149647-78-9
[ Name ]:
Vorinostat(SAHA)
[Synonym ]:
SAHA
Suberoylanilidehydroxamic Acid
N-Hydroxy-N'-phenyloctanediamide
M344
Vorinostat/SAHA
Vorinostat
suberoylanilide hydroxamic acid
suberanilohydroxamic acid
Zolinza
Octanediamide, N-hydroxy-N-phenyl-
Biological Activity
[Description]:
[Related Catalog]:
[Target]
HDAC1:10 nM (ID50)
HDAC3:20 nM (ID50)
HDAC2
HDAC7
HDAC11
Mitophagy
Autophagy
[In Vitro]
[In Vivo]
[Cell Assay]
[Animal admin]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Melting Point ]:
161-162°C
[ Molecular Formula ]:
C14H20N2O3
[ Molecular Weight ]:
264.320
[ Exact Mass ]:
264.147400
[ PSA ]:
78.43000
[ LogP ]:
0.86
[ Index of Refraction ]:
1.567
[ Storage condition ]:
-20°C Freezer
MSDS
Safety Information
[ Symbol ]:
GHS08
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H341-H360
[ Precautionary Statements ]:
P201-P281-P308 + P313
[ Hazard Codes ]:
T,Xn
[ Risk Phrases ]:
R61:May cause harm to the unborn child. R20/21:Harmful by inhalation and in contact with skin . R36:Irritating to the eyes. R36/37/38:Irritating to eyes, respiratory system and skin . R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
[ Safety Phrases ]:
S53-S45-S24/25-S22
[ RIDADR ]:
UN 2265 3/PG 3
[ WGK Germany ]:
3
[ RTECS ]:
SJ7453000
[ HS Code ]:
29349990
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2924299090
[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Articles
PLoS Biol. 12(1) , e1001758, (2014)
Type III interferon (IFN-λ) exhibits potent antiviral activity similar to IFN-α/β, but in contrast to the ubiquitous expression of the IFN-α/β receptor, the IFN-λ receptor is restricted to cells of ep...
Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Biochem. Pharmacol. 94(2) , 79-90, (2015)
Non-Small Cell Lung Cancer (NSCLC) remains an aggressive and fatal disease with low responsiveness to chemotherapy, frequent drug resistance development and metastatic behavior. Platinum-based therapy...
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Blood Cancer J. 5 , e312, (2015)
Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IR...